Webster Bank N. A. bought a new stake in Crispr Therapeutics AG (NASDAQ:CRSP) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 420 shares of the company’s stock, valued at approximately $26,000.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in CRSP. Farmers & Merchants Trust Co of Chambersburg PA acquired a new stake in shares of Crispr Therapeutics during the fourth quarter worth $26,000. State Street Corp grew its stake in shares of Crispr Therapeutics by 2.1% during the third quarter. State Street Corp now owns 37,103 shares of the company’s stock worth $1,521,000 after purchasing an additional 758 shares during the period. Balyasny Asset Management LLC acquired a new stake in shares of Crispr Therapeutics during the second quarter worth $5,165,000. Millennium Management LLC acquired a new stake in shares of Crispr Therapeutics during the third quarter worth $4,366,000. Finally, Bank of New York Mellon Corp grew its stake in shares of Crispr Therapeutics by 116.5% during the second quarter. Bank of New York Mellon Corp now owns 33,091 shares of the company’s stock worth $1,559,000 after purchasing an additional 17,810 shares during the period. 49.84% of the stock is owned by institutional investors.
Shares of Crispr Therapeutics stock opened at $54.20 on Thursday. The firm has a market cap of $3.02 billion, a price-to-earnings ratio of -117.83 and a beta of 3.20. The stock’s 50-day moving average is $61.60 and its 200-day moving average is $52.66. Crispr Therapeutics AG has a one year low of $29.34 and a one year high of $74.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32.
Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, beating analysts’ consensus estimates of ($0.95) by $3.35. The company had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. On average, equities analysts expect that Crispr Therapeutics AG will post 0.65 EPS for the current year.
A number of equities research analysts recently commented on the company. Canaccord Genuity lifted their price objective on Crispr Therapeutics from $72.00 to $80.00 and gave the stock a “positive” rating in a research note on Wednesday, November 20th. ValuEngine lowered Crispr Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, January 3rd. Piper Jaffray Companies reiterated a “buy” rating and set a $104.00 target price on shares of Crispr Therapeutics in a report on Monday, December 16th. Wells Fargo & Co reiterated a “buy” rating on shares of Crispr Therapeutics in a report on Friday, December 6th. Finally, Chardan Capital reiterated a “buy” rating and set a $72.50 target price on shares of Crispr Therapeutics in a report on Monday, November 18th. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and twelve have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $75.95.
In other news, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the sale, the president now directly owns 33,618 shares in the company, valued at $2,353,260. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total value of $412,500.00. Following the completion of the sale, the director now owns 7,500 shares in the company, valued at $412,500. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 48,618 shares of company stock worth $3,230,760. Corporate insiders own 21.40% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Further Reading: Balanced Fund
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.